Abstract: The present invention relates to the combined use of a PPAR? agonist and metformin for decreasing serum triglycerides.

Abstract: The present invention relates to the use of a ppar? agonist to treat patients suffering from weight gain associated with a ppar? agonist treatment.

Abstract: The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either aspirin or clopidogreL Such a pharmaceutical combination of an inhibitor of platelet aggregation and a fÊbrate is expected to be useful in the treatment and/or prevention of myocardial infarction (heart attack), cardiac arrest, peripheral vascular disease (including symptomatic carotid artery disease), congestive heart failure, ischemic heart disease, angina pectoris (including unstable angina), sudden cardiac death, unstable angina, as well as cerebrovascular events such as cerebral infarction, cerebral thrombosis, cerebral ischemia and transient ischemic attack, disorders related to bypass operations (angioplasty), fitting of endovascular prostheses and restenosis, and inflammatory disorders, including arthritic conditions such as rheumatoid arthritis and osteoarthritis, as well as asthma or related airway or resp

Abstract: The present invention relates to the use of a fibrate and orlistat to treat patients suffering from obesity.

Abstract: The present invention relates to anti-obesity pharmaceutical compositions comprising orlistat and metformin and to the use of combinations of metformin and orlistat to treat patients suffering from obesity.

Abstract: A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, and obesity.

Abstract: The present invention relates to the combined use of a PPAR? agonist and metformin for decreasing serum triglycerides.

Abstract: The invention relates to 2-thiohydantoin compounds selected from compounds of general formula (I): in which, in particular, one of the radicals R1 and R2 comprises two aromatic rings in the structure or is the dibenzofuranyl group, R3 is a hydrogen atom, a halogen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, a hydroxyl group, a phenyl group or a benzyl group, R4 is a hydrogen atom, a halogen atom or a C1-C4 alkyl group, and their addition salts with a non-toxic acid, especially the pharmaceutically acceptable salts. It further relates to the process for their preparation, to the pharmaceutical compositions in which they are present, and to their use as pharmacologically active substances, especially in the case of the treatment of diabetes, diseases due to hyperglycemia, hypertriglyceridemia, dyslipidemia or obesity.

Abstract: The present invention relates to the use of a ppar&agr; agonist to treat patients suffering from weight gain associated with a ppar&ggr; agonist treatment.